These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 24485802)

  • 1. Different biological and prognostic breast cancer populations identified by FDG-PET in sentinel node-positive patients: results and clinical implications after eight-years follow-up.
    Agresti R; Crippa F; Sandri M; Martelli G; Tagliabue E; Alessi A; Pellitteri C; Maccauro M; Maugeri I; Barbara P; Rampa M; Moscaroli A; Ferraris C; Carcangiu ML; Bianchi G; Greco M; Bombardieri E
    Breast; 2014 Aug; 23(4):334-40. PubMed ID: 24485802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 99mTc-Tetrofosmin pinhole-SPECT (P-SPECT) and radioguided sentinel node (SN) biopsy and in breast cancer axillary lymph node staging.
    Spanu A; Dettori G; Chessa F; Porcu A; Cottu P; Solinas P; Falchi A; Solinas ME; Scanu AM; Nuvoli S; Madeddu G
    Cancer Biother Radiopharm; 2001 Dec; 16(6):501-13. PubMed ID: 11789027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients.
    Dalus K; Reitsamer R; Holzmannhofer J; Rendl G; Pirich C; Kronberger C; Rettenbacher L
    Nuklearmedizin; 2011; 50(1):33-8. PubMed ID: 21336417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases.
    Veronesi U; De Cicco C; Galimberti VE; Fernandez JR; Rotmensz N; Viale G; Spano G; Luini A; Intra M; Veronesi P; Berrettini A; Paganelli G
    Ann Oncol; 2007 Mar; 18(3):473-8. PubMed ID: 17164229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG-PET for axillary lymph node staging in primary breast cancer.
    Crippa F; Gerali A; Alessi A; Agresti R; Bombardieri E
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S97-102. PubMed ID: 15133635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of Extracapsular Invasion at Metastatic Sentinel Nodes and Non-sentinel Lymph Nodal Metastases by FDG-PET in Cases with Breast Cancer.
    Fujii T; Yajima R; Tatsuki H; Kuwano H
    Anticancer Res; 2016 Apr; 36(4):1785-9. PubMed ID: 27069160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accurate staging with internal mammary chain sentinel node biopsy for breast cancer.
    Gnerlich JL; Barreto-Andrade JC; Czechura T; John JR; Turk MA; Kennedy TJ; Winchester DJ
    Ann Surg Oncol; 2014 Feb; 21(2):368-74. PubMed ID: 24046119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative FDG-PET for axillary metastases in patients with breast cancer.
    Chung A; Liou D; Karlan S; Waxman A; Fujimoto K; Hagiike M; Phillips EH
    Arch Surg; 2006 Aug; 141(8):783-8; discussion 788-9. PubMed ID: 16924086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer.
    Gil-Rendo A; Zornoza G; García-Velloso MJ; Regueira FM; Beorlegui C; Cervera M
    Br J Surg; 2006 Jun; 93(6):707-12. PubMed ID: 16622900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
    Crippa F; Agresti R; Seregni E; Greco M; Pascali C; Bogni A; Chiesa C; De Sanctis V; Delledonne V; Salvadori B; Leutner M; Bombardieri E
    J Nucl Med; 1998 Jan; 39(1):4-8. PubMed ID: 9443729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonvisualization of axillary sentinel node during lymphoscintigraphy: is there a pathologic significance in breast cancer?
    Brenot-Rossi I; Houvenaeghel G; Jacquemier J; Bardou VJ; Martino M; Hassan-Sebbag N; Pasquier J
    J Nucl Med; 2003 Aug; 44(8):1232-7. PubMed ID: 12902412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer.
    García Vicente AM; Soriano Castrejón A; Cruz Mora MÁ; Ortega Ruiperez C; Espinosa Aunión R; León Martín A; González Ageitos A; Van Gómez López O
    Rev Esp Med Nucl Imagen Mol; 2014; 33(1):1-5. PubMed ID: 23707190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
    Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
    Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative dynamic lymphoscintigraphy predicts sentinel lymph node metastasis in patients with early breast cancer.
    Nakashima K; Kurebayashi J; Sonoo H; Tanaka K; Ikeda M; Shiiki S; Yamamoto Y; Nomura T; Sohda M; Seki M; Miyake A; Moriya T; Sadahira Y; Mimura H; Fukunaga M
    Breast Cancer; 2010; 17(1):17-21. PubMed ID: 19466508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of indication for sentinel lymph node biopsy in clinical node-negative breast cancer using preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging.
    Taira N; Ohsumi S; Takabatake D; Hara F; Takashima S; Aogi K; Takashima S; Inoue T; Sugata S; Nishimura R
    Jpn J Clin Oncol; 2009 Jan; 39(1):16-21. PubMed ID: 18997183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla - Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial.
    Sávolt Á; Péley G; Polgár C; Udvarhelyi N; Rubovszky G; Kovács E; Győrffy B; Kásler M; Mátrai Z
    Eur J Surg Oncol; 2017 Apr; 43(4):672-679. PubMed ID: 28139362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: clinical evaluation and alternative management.
    Greco M; Crippa F; Agresti R; Seregni E; Gerali A; Giovanazzi R; Micheli A; Asero S; Ferraris C; Gennaro M; Bombardieri E; Cascinelli N
    J Natl Cancer Inst; 2001 Apr; 93(8):630-5. PubMed ID: 11309439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer.
    Aukema TS; Straver ME; Peeters MJ; Russell NS; Gilhuijs KG; Vogel WV; Rutgers EJ; Olmos RA
    Eur J Cancer; 2010 Dec; 46(18):3205-10. PubMed ID: 20719497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
    Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
    J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of the lymphoscintigraphy in the evaluation of non-axillary sentinel lymph node localization in breast cancer.
    Gherghe M; Bordea C; Blidaru A
    Chirurgia (Bucur); 2015; 110(1):26-32. PubMed ID: 25800312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.